May 2nd 2024
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
February 27th 2024
February 18th 2024
Zolbetuximab/Chemo Up Front Yields Benefit in CLDN18.2+ Advanced Gastric/GEJ Cancer
January 20th 2023Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer Types
December 15th 2022The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Zolbetuximab Reaches PFS End Point in CLDN18.2+ HER2– Advanced/Metastatic Gastric/GEJ Adenocarcinoma
November 17th 2022Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Fruquintinib/Paclitaxel Meets PFS End Point in Second-Line Gastric Cancer Trial
November 16th 2022Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.
Bemarituzumab Plus mFOLFOX6 Demonstrates Promising Clinical Efficacy in Advanced Gastric Cancer
November 4th 2022Data from the phase 2 FIGHT study indicated that the monoclonal antibody bemarituzumab may be a promising treatment when combined with mFOLFOX6 for patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
April 16th 2021The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.
Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup
April 10th 2021Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.